Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 inact mut Adavosertib + Carboplatin + Paclitaxel ovarian cancer sensitive detail...
TP53 wild-type Ad.p53-DC vaccine ovarian cancer predicted - sensitive detail...
TP53 wild-type p53-SLP vaccine ovarian cancer no benefit detail...
Unknown unknown ENMD-2076 ovarian cancer not applicable detail...
MET positive Altiratinib ovarian cancer predicted - sensitive detail...
Unknown unknown Nintedanib ovarian cancer not applicable detail...
KRAS mutant Alpelisib + Binimetinib ovarian cancer sensitive detail...
Unknown unknown MLN4924 ovarian cancer not applicable detail...
Unknown unknown Cediranib + Olaparib ovarian cancer not applicable detail...
Unknown unknown Docetaxel + Vandetanib ovarian cancer no benefit detail...
Unknown unknown Cabozantinib ovarian cancer not applicable detail...
Unknown unknown Axitinib + Carboplatin + Paclitaxel ovarian cancer not applicable detail...
Unknown unknown Itraconazole ovarian cancer not applicable detail...
Unknown unknown Paclitaxel + Vistusertib ovarian cancer not applicable detail...
Unknown unknown Sunitinib ovarian cancer not applicable detail...
Unknown unknown Abemaciclib ovarian cancer not applicable detail...
Unknown unknown VS-5584 ovarian cancer not applicable detail...
HRAS mutant Alpelisib + Binimetinib ovarian cancer predicted - sensitive detail...
Unknown unknown Buparlisib + Trametinib ovarian cancer not applicable detail...
BRCA1 inact mut Niraparib ovarian cancer sensitive detail...
BRCA2 inact mut Olaparib ovarian cancer sensitive detail...
BRCA1 inact mut Olaparib ovarian cancer sensitive detail...
Unknown unknown REGN421 ovarian cancer not applicable detail...
ARID1A mutant GSK126 ovarian cancer sensitive detail...
KRAS mutant CI-1040 ovarian cancer sensitive detail...
BRAF V600E CI-1040 ovarian cancer sensitive detail...
ARID1A dec exp GSK126 ovarian cancer sensitive detail...
ARID1A mutant UNC1999 ovarian cancer sensitive detail...
ARID1A wild-type GSK126 ovarian cancer no benefit detail...
Unknown unknown Carboplatin + Nintedanib + Paclitaxel ovarian cancer not applicable detail...
Unknown unknown Cisplatin + Uprosertib ovarian cancer not applicable detail...
Unknown unknown Conatumumab + Ganitumab ovarian cancer not applicable detail...
TP53 R248Q ReACp53 ovarian cancer sensitive detail...
TP53 R248Q APR-246 + Cisplatin ovarian cancer sensitive detail...
TP53 loss ReACp53 ovarian cancer no benefit detail...
Unknown unknown RO5520985 ovarian cancer not applicable detail...
ARID1A dec exp Talazoparib ovarian cancer sensitive detail...
TP53 loss Cisplatin + LB-100 ovarian cancer sensitive detail...
TP53 inact mut Cisplatin + LB-100 ovarian cancer sensitive detail...
Unknown unknown Cisplatin + LB-100 ovarian cancer not applicable detail...
Unknown unknown AZD1480 ovarian cancer not applicable detail...
Unknown unknown SST0116CL1 ovarian cancer not applicable detail...
BRAF N486_P490del LY3009120 ovarian cancer sensitive detail...
BRAF N486_P490del Trametinib ovarian cancer sensitive detail...
BRAF N486_P490del Vemurafenib ovarian cancer resistant detail...
BRAF N486_P490del Dabrafenib ovarian cancer predicted - resistant detail...
TP53 S241F Ganetespib ovarian cancer sensitive detail...
Unknown unknown JNJ-54302833 ovarian cancer not applicable detail...
Unknown unknown TAK-960 ovarian cancer not applicable detail...
Unknown unknown Bevacizumab ovarian cancer not applicable detail...
Unknown unknown AIM-100 ovarian cancer not applicable detail...
Unknown unknown ST7612AA1 ovarian cancer not applicable detail...
AKT1 wild-type Uprosertib ovarian cancer predicted - sensitive detail...
TP53 mutant Nutlin-3 ovarian cancer no benefit detail...
TP53 mutant Etoposide + Nutlin-3 ovarian cancer sensitive detail...
TP53 inact mut Cisplatin + Nutlin-3 ovarian cancer sensitive detail...
TP53 del Nutlin-3 ovarian cancer no benefit detail...
TP53 del Cisplatin + Nutlin-3 ovarian cancer sensitive detail...
TP53 del Etoposide + Nutlin-3 ovarian cancer sensitive detail...
Unknown unknown AB61 ovarian cancer not applicable detail...
Unknown unknown BAY1161909 ovarian cancer not applicable detail...
Unknown unknown BAY1217389 ovarian cancer not applicable detail...
Unknown unknown Paclitaxel + TVB-2640 ovarian cancer not applicable detail...
Unknown unknown Vandetanib ovarian cancer no benefit detail...
NRAS mutant Trametinib ovarian cancer sensitive detail...
BRCA1 mut TP53 Y220C Carboplatin + VX-970 ovarian cancer sensitive detail...
Unknown unknown Cisplatin + TRX-E-002-1 ovarian cancer not applicable detail...
Unknown unknown TRX-E-002-1 ovarian cancer not applicable detail...
Unknown unknown Paclitaxel + TRX-E-002-1 ovarian cancer not applicable detail...
BRCA1 inact mut Cyclophosphamide + Veliparib ovarian cancer no benefit detail...
BRCA2 inact mut Cyclophosphamide + Veliparib ovarian cancer no benefit detail...
Unknown unknown Bevacizumab + Everolimus ovarian cancer not applicable detail...
NOTCH1 positive LY3039478 ovarian cancer sensitive detail...
Unknown unknown Napabucasin ovarian cancer not applicable detail...
Unknown unknown Demcizumab ovarian cancer not applicable detail...
Unknown unknown Demcizumab + Paclitaxel ovarian cancer not applicable detail...
Unknown unknown Alisertib ovarian cancer not applicable detail...
Unknown unknown Carboplatin + Ipafricept + Paclitaxel ovarian cancer not applicable detail...
BRCA1 mutant Irinotecan + Veliparib ovarian cancer predicted - sensitive detail...
BRCA2 mutant Irinotecan + Veliparib ovarian cancer predicted - sensitive detail...
FGFR2-FAM76A BGJ398 ovarian cancer sensitive detail...
Unknown unknown Carboplatin + Cediranib ovarian cancer not applicable detail...
ERBB2 positive Hertuzumab-vc-MMAE ovarian cancer sensitive detail...
Unknown unknown Niraparib ovarian cancer not applicable detail...
KRAS mutant OSI-027 ovarian cancer sensitive detail...
PTEN loss OSI-027 ovarian cancer sensitive detail...
BRCA1 mutant Rucaparib ovarian cancer sensitive detail...
BRCA2 mutant Rucaparib ovarian cancer sensitive detail...
BRCA1 mutant Niraparib ovarian cancer predicted - sensitive detail...
BRCA2 mutant Niraparib ovarian cancer predicted - sensitive detail...
BRCA1 wild-type BRCA2 wild-type Niraparib ovarian cancer predicted - sensitive detail...
FGFR2 amp BAY1187982 ovarian cancer sensitive detail...
Unknown unknown ABT-737 + AZD8055 + Trametinib ovarian cancer not applicable detail...
Unknown unknown ABT-737 + BEZ235 + Trametinib ovarian cancer not applicable detail...
Unknown unknown ABT-737 + MK2206 + Trametinib ovarian cancer not applicable detail...
TP53 R280K APR-246 + Cisplatin ovarian cancer sensitive detail...
TP53 P151H APR-246 + Cisplatin ovarian cancer sensitive detail...
TP53 L111Q APR-246 + Cisplatin ovarian cancer sensitive detail...
TP53 Y163H APR-246 + Cisplatin ovarian cancer sensitive detail...
TP53 P278R APR-246 + Cisplatin ovarian cancer sensitive detail...
BRCA1 wild-type Talazoparib + Temozolomide ovarian cancer sensitive detail...
Unknown unknown KPT-185 ovarian cancer not applicable detail...
Unknown unknown Cisplatin + KPT-185 ovarian cancer not applicable detail...
Unknown unknown Selinexor ovarian cancer not applicable detail...
Unknown unknown Cisplatin + Selinexor ovarian cancer not applicable detail...
TP53 R175H NSC319726 ovarian cancer sensitive detail...
Unknown unknown JI-101 ovarian cancer not applicable detail...
Unknown unknown Pegylated liposomal-doxorubicin + Trebananib ovarian cancer not applicable detail...
Unknown unknown Cediranib ovarian cancer not applicable detail...
Unknown unknown PF-06647263 ovarian cancer not applicable detail...
Unknown unknown BGB-A317 + Pamiparib ovarian cancer not applicable detail...
BRCA1 mutant Talazoparib ovarian cancer predicted - sensitive detail...
BRCA2 mutant Talazoparib ovarian cancer predicted - sensitive detail...
Unknown unknown ETP-46464 + Radiotherapy ovarian cancer not applicable detail...
Unknown unknown Cisplatin + ETP-46464 ovarian cancer not applicable detail...
Unknown unknown Carboplatin + ETP-46464 ovarian cancer not applicable detail...
Unknown unknown Cisplatin + VE-821 ovarian cancer not applicable detail...
AKT1 Q79K Capivasertib ovarian cancer predicted - sensitive detail...
Unknown unknown S2101 ovarian cancer not applicable detail...
TP53 mutant Adavosertib + Carboplatin ovarian cancer predicted - sensitive detail...
KRAS mut TP53 G105C TP53 V157fs Adavosertib + Carboplatin ovarian cancer predicted - sensitive detail...
BRCA1 mut TP53 E298* Adavosertib + Carboplatin ovarian cancer predicted - sensitive detail...
TP53 Y163* Adavosertib + Carboplatin ovarian cancer predicted - sensitive detail...
TP53 P98fs TP53 R175C TP53 S215G Adavosertib + Carboplatin ovarian cancer predicted - resistant detail...
Unknown unknown Cisplatin + NU6027 ovarian cancer not applicable detail...
TP53 positive NU6027 + Temozolomide ovarian cancer predicted - sensitive detail...
BRCA1 mutant Pamiparib ovarian cancer predicted - sensitive detail...
BRCA2 mutant Pamiparib ovarian cancer predicted - sensitive detail...
Unknown unknown Cediranib + Durvalumab + Olaparib ovarian cancer not applicable detail...
Unknown unknown Capivasertib + Olaparib ovarian cancer not applicable detail...
Unknown unknown Lurbinectedin ovarian cancer not applicable detail...
ERBB2 positive PRS-343 ovarian cancer sensitive detail...
KRAS act mut Gedatolisib + PD-0325901 ovarian cancer predicted - sensitive detail...
Unknown unknown SCH 58500 ovarian cancer not applicable detail...
Unknown unknown Ad5CMV-p53 gene ovarian cancer not applicable detail...
TP53 over exp HLA-A2 p53:264-272 vaccine ovarian cancer predicted - sensitive detail...
Unknown unknown C3742 + Cisplatin ovarian cancer not applicable detail...
Unknown unknown PV1019 + Topotecan ovarian cancer not applicable detail...
Unknown unknown Camptothecin + PV1019 ovarian cancer not applicable detail...
BRCA1 E23Vfs*17 BRCA1 T37Qfs*13 Carboplatin ovarian cancer predicted - resistant detail...
BRCA1 E23Vfs*17 BRCA1 E29Sfs*2 BRCA1 K38Sfs*12 Carboplatin ovarian cancer predicted - resistant detail...
ERBB2 mutant Neratinib ovarian cancer no benefit detail...
ERBB2 positive MI130004 ovarian cancer sensitive detail...
ARID1A loss unspecified PD-L1 antibody ovarian cancer predicted - sensitive detail...
Unknown unknown Tisotumab Vedotin ovarian cancer not applicable detail...
Unknown unknown Nivolumab + Varlilumab ovarian cancer not applicable detail...
Unknown unknown MEDI3617 ovarian cancer not applicable detail...
BRCA2 loss APTO-253 ovarian cancer predicted - sensitive detail...
ERBB2 positive ARX-788 ovarian cancer sensitive detail...
Unknown unknown Selumetinib + SHP099 ovarian cancer not applicable detail...
Unknown unknown Roniciclib ovarian cancer not applicable detail...
ERBB2 amp Pertuzumab + Trastuzumab ovarian cancer predicted - sensitive detail...
ERBB2 over exp Pertuzumab + Trastuzumab ovarian cancer predicted - sensitive detail...
BRAF V600E Vemurafenib ovarian cancer predicted - sensitive detail...
Unknown unknown Avelumab ovarian cancer not applicable detail...
Unknown unknown SNS-032 ovarian cancer not applicable detail...
Unknown unknown SNS-032 + unspecified PD-1 antibody ovarian cancer not applicable detail...
ARID1A dec exp Buthionine sufoximine ovarian cancer predicted - sensitive detail...
ARID1A dec exp APR-246 ovarian cancer predicted - sensitive detail...
Unknown unknown MBG453 ovarian cancer not applicable detail...
Unknown unknown MBG453 + Spartalizumab ovarian cancer not applicable detail...
Unknown unknown Paclitaxel + VB-111 ovarian cancer not applicable detail...
BRCA1 mutant BAY1895344 ovarian cancer predicted - sensitive detail...
Unknown unknown Navicixizumab ovarian cancer not applicable detail...
BRCA1 mutant Olaparib ovarian cancer sensitive detail...
BRCA2 mutant Olaparib ovarian cancer sensitive detail...
BRCA2 inact mut Rucaparib ovarian cancer sensitive detail...
BRCA1 inact mut Rucaparib ovarian cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00194714 Phase Ib/II HER2 Vaccine Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab Active, not recruiting
NCT00565851 Phase III Gemcitabine Docetaxel + Paclitaxel Carboplatin Bevacizumab Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Active, not recruiting
NCT00892736 Phase I Veliparib Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy Completed
NCT00993655 Phase III Cisplatin Paclitaxel Carboplatin Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed
NCT01031381 Phase II Bevacizumab + Everolimus Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer Completed
NCT01132014 Phase I Bevacizumab Dacarbazine Autologous OC-DC Vaccine in Ovarian Cancer Completed
NCT01218867 Phase Ib/II Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes Completed
NCT01248949 Phase I Bevacizumab MEDI3617 Gemcitabine Carboplatin Paclitaxel A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors Completed
NCT01264432 Phase I Veliparib Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer Completed
NCT01286987 Phase I Talazoparib Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed
NCT01292655 Phase I BMS-906024 Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors Completed
NCT01305213 Phase Ib/II Fosbretabulin Bevacizumab Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed
NCT01312376 Phase I Fludarabine Cyclophosphamide Bevacizumab CD3/CD28 stimulated/primed autologous Ts OC-DC vaccine Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer Unknown status
NCT01325441 Phase Ib/II Napabucasin + Paclitaxel A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Recruiting
NCT01357161 Phase II Carboplatin Adavosertib Paclitaxel A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) Completed
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Active, not recruiting
NCT01384253 Phase I 212Pb-TCMC-Trastuzumab + Trastuzumab Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy Completed
NCT01445418 Phase I Olaparib Carboplatin AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer Completed
NCT01459380 Phase I Carboplatin Doxorubicin Veliparib Bevacizumab Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed
NCT01482715 Rucaparib A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) Completed
NCT01493505 Phase III Carboplatin Paclitaxel Trebananib TRINOVA-3 Terminated
NCT01551745 Phase II Bevacizumab + FANG vaccine Salvage Ovarian FANG Vaccine + Bevacizumab Completed
NCT01579812 Phase II Metformin Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients Completed
NCT01610206 Phase II Gemcitabine + Pazopanib Gemcitabine A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer Active, not recruiting
NCT01616303 Phase II Carboplatin + Oregovomab + Paclitaxel Carboplatin + Paclitaxel A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer Completed
NCT01621542 Phase I WT2725 Clinical Study of WT2725 in Patients With Advanced Malignancies Completed
NCT01623349 Phase I Alpelisib + Olaparib Buparlisib + Olaparib Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer Active, not recruiting
NCT01652079 Phase II Bevacizumab + CRLX101 CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer Completed
NCT01663857 Phase Ib/II Ralimetinib Carboplatin + Gemcitabine A Study of LY2228820 for Recurrent Ovarian Cancer Completed
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Recruiting
NCT01831089 Phase I Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed
NCT01847274 Phase III Niraparib A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Active, not recruiting
NCT01874353 Phase III Olaparib Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Active, not recruiting
NCT01920061 Phase I Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) Recruiting
NCT01928394 Phase Ib/II Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT01952249 Phase Ib/II Demcizumab Paclitaxel A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian Terminated
NCT01962948 Phase II Paclitaxel Ganetespib Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Terminated
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Recruiting
NCT01972516 Phase II Tivozanib Tivozanib As Maintenance Therapy In GYN Terminated
NCT01989546 Phase Ib/II Talazoparib Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations Recruiting
NCT01995188 Phase I Bevacizumab + Carboplatin + DNIB0600A Carboplatin + DNIB0600A A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Patients With Ovarian Cancer Completed
NCT01999738 Phase I EC1456 Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Completed
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed
NCT02035345 FDA approved Carboplatin Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated
NCT02046421 Phase I Mifepristone Carboplatin + Gemcitabine Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Completed
NCT02050009 Phase I Carboplatin + Metformin + Paclitaxel Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Withdrawn
NCT02100007 Phase Ib/II ME-344 + Topotecan ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors Terminated
NCT02117817 Phase I Buparlisib + Nab-paclitaxel Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer Withdrawn
NCT02118285 Phase I Aldesleukin Epacadostat Cyclophosphamide Fludarabine Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Completed
NCT02122809 Phase I Chiauranib Phase I Study of Chiauranib in Patients With Advanced Solid Tumors Completed
NCT02122861 Phase I ID-LV305 A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 Completed
NCT02124421 Phase II Carboplatin + Paclitaxel Cisplatin + Paclitaxel Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer Recruiting
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202) Active, not recruiting
NCT02199171 Phase I Carboplatin Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer Completed
NCT02203513 Phase II Prexasertib A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer Recruiting
NCT02222922 Phase I Avelumab + PF-06647020 Fluconazole PF-06647020 A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors Active, not recruiting
NCT02269293 Phase I Carboplatin + Paclitaxel + Selinexor Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers Recruiting
NCT02298959 Phase I Aflibercept + Pembrolizumab Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors Recruiting
NCT02307240 Phase I CUDC-907 Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors Active, not recruiting
NCT02312245 Phase II Topotecan Doxorubicin Paclitaxel Gemcitabine Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting
NCT02323191 Phase I Atezolizumab + Emactuzumab A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors Recruiting
NCT02326844 Phase II Talazoparib BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment Terminated
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Active, not recruiting
NCT02335918 Phase Ib/II Nivolumab + Varlilumab A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Completed
NCT02340611 Phase II Cediranib + Olaparib A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib Completed
NCT02341625 Phase Ib/II BMS-986148 BMS-986148 + Nivolumab A Study of BMS-986148 in Patients With Select Advanced Solid Tumors Active, not recruiting
NCT02346747 Phase II FANG vaccine Phase II/III Trial of Maintenance Vigil for High Risk Stage III/IV Ovarian Cancer (VITAL) Active, not recruiting
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated
NCT02349958 Phase II Mitomycin C Cisplatin Doxorubicin Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Recruiting
NCT02387125 Phase I CMB305 A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 Completed
NCT02417753 Phase II AZD9150 AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites Terminated
NCT02419417 Phase Ib/II BMS986158 Paclitaxel Study of BMS-986158 in Subjects With Select Advanced Solid Tumors Recruiting
NCT02432690 Phase II BBI503 A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation Terminated
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting
NCT02433626 Phase I COTI-2 Cisplatin + COTI-2 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) Recruiting
NCT02437812 Phase II Paclitaxel Carboplatin Metformin Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma Recruiting
NCT02446600 Phase III Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal-doxorubicin Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Completed
NCT02452775 Phase I OC-L Autologous OC-L Vaccine and Ovarian Cancer Completed
NCT02476968 FDA approved Olaparib To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer (ORZORA) Active, not recruiting
NCT02487095 Phase Ib/II VX-970 Topotecan Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer Recruiting
NCT02498600 Phase II Ipilimumab Nivolumab Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Active, not recruiting
NCT02502266 Phase II Topotecan Paclitaxel Doxorubicin Olaparib Cediranib Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting
NCT02520154 Phase II Carboplatin + Paclitaxel Pembrolizumab Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer Recruiting
NCT02554812 Phase Ib/II Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Recruiting
NCT02558348 Phase Ib/II Anlotinib Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) Terminated
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed
NCT02575807 Phase Ib/II Epacadostat CRS-207 Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer Terminated
NCT02580058 Phase III Doxorubicin Avelumab A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer Active, not recruiting
NCT02584478 Phase Ib/II Anlotinib + Carboplatin + Paclitaxel Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) Recruiting
NCT02595892 Phase II VX-970 Gemcitabine Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting
NCT02606305 Phase I Bevacizumab Carboplatin Doxorubicin Mirvetuximab Soravtansine Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer Recruiting
NCT02627430 Phase I Onalespib + Talazoparib Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Withdrawn
NCT02627443 Phase II Carboplatin + Gemcitabine VX-970 Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Suspended
NCT02628535 Phase I MGD009 Safety Study of MGD009 in B7-H3-expressing Tumors Recruiting
NCT02631733 Phase I Irinotecan + Veliparib Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Suspended
NCT02631876 Phase II Paclitaxel + Pegylated liposomal-doxorubicin Gemcitabine Topotecan Mirvetuximab Soravtansine PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer Active, not recruiting
NCT02632448 Phase Ib/II Gemcitabine + LY2880070 LY2880070 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer Recruiting
NCT02646319 Phase I Nab-Rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Completed
NCT02649673 Phase Ib/II LCL161 + Topotecan LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies Recruiting
NCT02655016 Phase III Niraparib A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy Active, not recruiting
NCT02657889 Phase Ib/II Niraparib + Pembrolizumab Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO) Active, not recruiting
NCT02658214 Phase I Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors Active, not recruiting
NCT02681237 Phase I Cediranib + Olaparib A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer Active, not recruiting
NCT02734004 Phase Ib/II Durvalumab + Olaparib Bevacizumab + Durvalumab + Olaparib A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) Recruiting
NCT02737787 Phase I Nivolumab + WT1 vaccine A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer Active, not recruiting
NCT02760797 Phase I Emactuzumab + RO7009789 A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Completed
NCT02762981 Phase Ib/II Nab-paclitaxel + Relacorilant Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors Recruiting
NCT02799095 Phase I ALKS 4230 A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors Recruiting
NCT02839707 Phase II Atezolizumab + Bevacizumab + Pegylated liposomal-doxorubicin Atezolizumab + Pegylated liposomal-doxorubicin Bevacizumab + Pegylated liposomal-doxorubicin Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Active, not recruiting
NCT02923349 Phase Ib/II INCAGN01949 A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Completed
NCT02950064 Phase I BTP-114 A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Active, not recruiting
NCT02952248 Phase I BI 754091 A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours Recruiting
NCT02953782 Phase Ib/II Cetuximab + Hu5F9-G4 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer Recruiting
NCT02996825 Phase I Mirvetuximab Soravtansine Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer Recruiting
NCT03023319 Phase I Bosutinib + Pemetrexed Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Recruiting
NCT03026062 Phase II Tremelimumab Durvalumab + Tremelimumab Durvalumab Durvalumab and Tremelimumab in Combo Versus Sequential Recruiting
NCT03029598 Phase Ib/II Carboplatin + Pembrolizumab Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting
NCT03030287 Phase I OMP-305B83 + Paclitaxel A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer Active, not recruiting
NCT03056833 Phase I Carboplatin + Paclitaxel + Ribociclib Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer Recruiting
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Recruiting
NCT03132922 Phase I Autologous MAGE-A4 C1032 TCR-modified T cells MAGE-A4c1032T for Multi-Tumor Recruiting
NCT03134638 Phase I SY-1365 A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors Recruiting
NCT03150810 Phase Ib/II Pamiparib + Temozolomide Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03154281 Phase I Everolimus + Niraparib Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast Recruiting
NCT03162627 Phase I Olaparib + Selumetinib Selumetinib and Olaparib in Solid Tumors Recruiting
NCT03188965 Phase I BAY1895344 First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Recruiting
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Recruiting
NCT03206177 Phase I Carboplatin + Galunisertib + Paclitaxel Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary Recruiting
NCT03239145 Phase I Pembrolizumab + Trebananib Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor Recruiting
NCT03283943 Phase I Durvalumab PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. Recruiting
NCT03292172 Phase I Atezolizumab + TEN-010 A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer Suspended
NCT03294694 Phase I Fulvestrant + Ribociclib + Spartalizumab Ribociclib + Spartalizumab Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer Recruiting
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Recruiting
NCT03342417 Phase II Ipilimumab + Nivolumab Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients Terminated
NCT03363776 Phase Ib/II BMS-986277 BMS-986277 + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers Recruiting
NCT03363893 Phase Ib/II ICEC0942 Fulvestrant + ICEC0942 Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies Recruiting
NCT03449108 Phase II Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna Iovance Alliance: LN-145 Across Multiple Tumor Types Recruiting
NCT03456700 Phase II Auranofin + Sirolimus Auranofin and Sirolimus in Treating Participants With Ovarian Cancer Suspended
NCT03508570 Phase I Nivolumab Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03552471 Phase I Mirvetuximab Soravtansine + Rucaparib Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Recruiting
NCT03565445 Phase I ASP1948 + Nivolumab ASP1948 A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors Recruiting
NCT03586661 Phase I Copanlisib + Niraparib Niraparib and Copanlisib in Treating Participants With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting
NCT03621982 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Recruiting
NCT03628677 Phase I AB154 AB154 + GLS-010 A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Recruiting
NCT03629756 Phase I AB928 + GLS-010 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Recruiting
NCT03663712 Phase I Talimogene laherparepvec Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO) Recruiting
NCT03667716 Phase I COM701 COM701 + Nivolumab COM701 in Subjects With Advanced Solid Tumors Recruiting
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Recruiting
NCT03717415 Phase Ib/II Carboplatin + Rebastinib A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors Recruiting
NCT03719326 Phase I AB928 + IPI-549 + Pegylated liposomal-doxorubicin AB928 + Pegylated liposomal-doxorubicin A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer and Gynecologic Malignancies Recruiting
NCT03761914 Phase Ib/II Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Recruiting
NCT03784378 Phase I RXDX-105 Continued Access to RXDX-105 Recruiting
NCT03797326 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Recruiting
NCT03872947 Phase I Pembrolizumab + TRK-950 Carboplatin + Gemcitabine + TRK-950 Imiquimod + TRK-950 Paclitaxel + Ramucirumab + TRK-950 Nivolumab + TRK-950 Cisplatin + Gemcitabine + TRK-950 Fluorouracil + Irinotecan + Leucovorin + TRK-950 A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Recruiting
NCT03968406 Phase I Talazoparib Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Not yet recruiting
NCT03992131 Phase Ib/II Lucitanib + Rucaparib Rucaparib + Sacituzumab govitecan A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) Recruiting